DIŌKO VENTURES INVESTMENT Criteria

Diōko Ventures targets early stage investment opportunities with a focus on healthcare services and technology meeting the following criteria: 

Healthcare services and technology startups led by strong management teams with sector specific expertise

Ventures at an early stage enabling the fund to obtain meaningful ownership and help the company as they scale

Investment opportunities that are driving change in healthcare and helping current institutions adapt to a world in which they must be better, faster, and cheaper.

The fund’s average investment Size is $300,000 - $1,200,000 in companies with a $50,000+ Annual Revenue Run Rate. The fund has a focus on Western North Carolina, but has the ability to invest anywhere in the U.S.  



Diōko Ventures INVESTMENT THESIS REPORTS

Diōko is actively interested in making investments across the following areas of healthcare as we believe they are ripe for improvement by innovative startups. 

pal.png

End of Life and Palliative Care

End-of-life care is an important part of the care continuum for patients and the families of patients with terminal conditions or those encroaching upon old age. Palliative care is one option for end-of-life care and is specifically focused on symptom and pain management for patients with serious illnesses; it is not necessarily limited to patients in their last days or months of life and can be administered across a variety of care settings (from home to hospital). 

onc.png

Oncology Tech

The Oncology space offers an attractive market opportunity for the rapidly growing number of cancer-focused startups. The transition to value-based reimbursement is fueling this market opportunity by pressuring providers to improve processes and reduce costs. Although relatively new, MIPS and the Oncology Care Model supply the incentive for providers to adopt technologies that succeed in making cancer care faster, better, and cheaper. Skeptics are pessimistic about the longevity of MIPS as Congress takes aim at the sometimes-excessive reporting requirements, but experts agree that the concept of value-based reimbursement is part of healthcare’s future. Additionally, tech solutions can help to mitigate the negative trends in oncology such as increasingly cumbersome reporting requirements, the rising rates of oncologist burnout, and the challenges of patient treatment adherence. To solve these problems, software platforms will assist with clinical standardization, precision treatment planning, and patient symptom reporting, reducing costs for providers."

care.png

Outsourced Care Management

The U.S. healthcare system continues to shift toward a value-based care model as payers incentivize treatment value (value-based care) over treatment volume (fee-for-service). Innovators and entrepreneurs are forming new businesses focused on delivering better care outcomes at a lower cost to support this shift from fee-for-service to value-based care. These startups work directly with payers, patients, and providers to generate solutions to improve patients’ health by rethinking delivery of care and disease prevention. Many of them aim to rein in runaway healthcare spending by focusing on the costliest diseases and conditions, and by charging payers a flat (often monthly) fee for services rendered.

Block.png

The Nexus of Blockchain and Healthcare

While it is still very early days to fully comprehend blockchain’s role in healthcare, we  believe that this technology has the potential to address some of the top concerns in data sharing and security within the U.S. healthcare system. We are actively seeking investment opportunities into companies using blockchain to solve unique problems that widely adopted technology solutions fail to address. Initial Coin Offerings have changed the role venture capital firms play in funding blockchain startups; however, because of the unique complexity and difficulty of building a healthcare startup (in relation to other industries), having a value-added capital partner ally who understands the intricacies of healthcare can create an unfair advantage over competitors without these types of investors.

Pill.png

Opioid Abuse

The opioid epidemic offers three clear entry points for startups. A biotech enabled solution will yield the most profit and has a clear path to commercialization. A patient or addict centered solution may gain user traction but has an unclear path to profitability. The clinician centered solutions are gaining modest traction; however, the value creation model is difficult to ascertain. Clinicians would benefit from software based tools, but the patients and payers absorb the costs associated with addiction. Therefore, a startup trying to enter this space would have to develop a product that provides benefits for both providers and payers to gain significant market penetration.